Boehringer Ingelheim Mexico today inaugurated its new manufacturing plant for the production of medicines for the treatment of diabetes, in which the company has invested MX$400 million. The chronic disease has become a great concern for Mexican authorities and currently has a prevalence rate of 9.5% in Mexico, while it is around 6% in other countries. Boehringer Ingelheim’s raison d’être for this major investment is to transform the life of patients by satisfying the need for more effective treatments.
Boehringer Ingelheim is the fifth largest pharmaceutical company in Mexico today, employing 1,800 professionals and technicians. The company grows above the market average and its sector competitors, and has a strong portfolio for several specialties including respiratory diseases, cardiology, diabetes, cancer, and hematology, as well as many of the most common OTC products like Lonol, Mucoangin, Bisolvon, and Isodine. The company’s aims to further expand its manufacturing operations in Mexico through this global production site of innovative antidiabetic medicines.
“The top priorities for Boehringer Ingelheim Mexico today include fostering the country as a clinical research hub, strengthening Mexico’s position as a global leader in the manufacture of oral solids complying with COFEPRIS and FDA requirements, pushing forward our plant in Guadalajara as a global platform for veterinary products, and setting up a global site for the manufacture of antidiabetic medicines, which is something to celebrate today”, Miguel Salazar, Director General of Boehringer Ingelheim Mexico, explained to the select audience invited to the inauguration.
Boehringer Ingelheim is a strong example of a multinational company investing heavily in Mexico, having invested MX$1 billion within three years. “Chronic diseases represent a serious threat for the population, and multinational companies such as Boehringer Ingelheim investing in Mexico are essential to the improvement public healthcare” Mikel Arriola, Comissioner of COFEPRIS, stated at the inauguration event. Arriola reiterated that today, Mexico has the shortest times for new drug registrations due to its Equivalence Agreement. “Not only has COFEPRIS improved the drug approval process, but also imports have been steadily substituted for efficient investments in the country due to a supportive business and regulatory environment” Arriola highlighted. The whole pharmaceutical landscape has certainly changed in recent years. One example of this is one of today’s most effective therapies for diabetes, Boehringer’s Jardiance®, which has a 77% lower price in Mexico than in the US, and it was launched in Mexico ahead of the US and Germany.
In the new plant, 40 million units of antidiabetic drugs will be produced annually, accounting for 1.2 trillion tablets. The medicine linagliptin will be produced both as a monotherapy and in combination with metformin in the plant. “Patients require different medicines according the stage of their disease. In the beginning they should receive metformin alone, and as the disease progresses, more specialized treatments are needed. Thus, we provide innovative solutions such as litagliptin alone and its combination with metformin, which reduce risk of cardiovascular death by 40% among diabetic patients”, Jorge del Río, Director of Prescription Medicines and Specialty Products at Boehringer, explained. The new plant has different areas and cutting edge technology for storage and mixture of active compounds, granulation, tablet production, coating, and packaging. It will be certified by Canada, FDA, and EMA standards and is intended to serve global markets by exporting 80% of its production.
Photographs kindly provided by Boehringer Ingelheim.